Hydrogen and Oxygen Mixture to Improve Cardiac Dysfunction and Myocardial Pathological Changes Induced by Intermittent Hypoxia in Rats.
Ya-Shuo Zhao, Ji-Ren An, Shengchang Yang, Peng Guan, Fu-Yang Yu, Wenya Li, Jie-Ru Li, Yajing Guo, Zhi-Min Sun, En-Sheng Ji · Oxidative medicine and cellular longevity · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The researchers found that H₂-O₂ mixture blocked c-Jun N-terminal kinase- (JNK-) MAPK activation, increased the ratio of Bcl-2/Bax, and inhibited caspase 3 cleavage to protect against CIH-induced cardiac apoptosis. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in rats. The researchers found that H₂-O₂ mixture blocked c-Jun N-terminal kinase- (JNK-) MAPK activation, increased the ratio of Bcl-2/Bax, and inhibited caspase 3 cleavage to protect against CIH-induced cardiac apoptosis.
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
67% inhaled H₂ concentration; reported treatment duration: 35 days. The researchers found that H₂-O₂ mixture blocked c-Jun N-terminal kinase- (JNK-) MAPK activation, increased the ratio of Bcl-2/Bax, and inhibited caspase 3 cleavage to protect against CIH-induced cardiac apoptosis. The authors concluded that H₂-O₂ mixture remarkably improved cardiac dysfunction and myocardial fibrosis.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment. The reported hydrogen concentration was 67% inhaled H₂ concentration. The reported treatment duration was 35 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.